PET Response Criteria in Solid Tumors
PERCIST is the metabolic counterpart to RECIST, defining tumor response on FDG-PET using quantitative uptake (SUL peak) rather than size alone. It categorizes complete, partial, stable, and progressive metabolic response based on percentage change in a standardized-uptake measure, capturing treatment effects that anatomic shrinkage can miss or lag. It is the reference radiologists and nuclear-medicine physicians reach for when a report needs to speak “metabolic response,” and it is frequently contrasted head-to-head with RECIST.
Defined metabolic response on FDG-PET by percentage change in SUL peak (CMR/PMR/SMD/PMD), the quantitative metabolic counterpart to RECIST.
Phase I study of Yttrium-90 radioembolization plus DEBIRI for colorectal liver metastases: maximum tolerated dose was 80 Gy, with considerable toxicity and limited response (RECIST ORR 9%).
Retrospective: RECIBM bone metastasis criteria had high agreement with MD Anderson, PERCIST, EORTC (κ=0.80–0.98) and reclassified 19% of 84 patients. Response was associated with OS (HR 0.07) and bone progression-free survival (HR 0.03).
Bone metastases, historically non-measurable by standard criteria, may become quantifiable with emerging methods, though specific accuracy numbers are not reported in the source.
RadPigeon is an independent radiology news digest and is not affiliated with or endorsed by Wahl et al.. “PERCIST” is a trademark of its owner and is named here only to refer to the system. Always consult the official source for the exact, current criteria.